AstraZeneca to Divest its Hypertension Therapies to Atnahs Pharma

Share this

AstraZeneca to Divest its Hypertension Therapies to Atnahs Pharma


  • AstraZeneca to receive $350M up front- up to $40M as commercial milestones b/w 2020 to 2022. Atnahs to get global commercial rights (Ex- US- India and Japan) of Inderal (propranolol)- Tenormin (atenolol)- Tenoretic (atenolol- chlorthalidone FD combination)- Zestril (lisinopril) and Zestoretic (lisinopril- hydrochlorothiazide FD combination)
  • AstraZeneca will retain rights in Japan and will continue to manufacture & supply the therapies during the transaction period. The divestiture is expected to be completed in Q1’20
  • Inderal and Tenormin are beta-blockers- used to treat angina hypertension and arrhythmias. Zestril is an ACE inhibitor indicated to treat hypertension- CHF- diabetic-related conditions and hypertensive renal disease

Click here ­to­ read full press release/ article 

Ref: AstraZeneca | Image: AstraZeneca

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions